Concepts (156)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bariatric Surgery | 9 | 2025 | 154 | 1.620 |
Why?
|
| Endocrine Surgical Procedures | 2 | 2023 | 7 | 1.340 |
Why?
|
| Obesity, Morbid | 8 | 2025 | 232 | 1.250 |
Why?
|
| Health Expenditures | 3 | 2025 | 136 | 1.230 |
Why?
|
| Parathyroidectomy | 3 | 2023 | 51 | 1.210 |
Why?
|
| Surgeons | 3 | 2023 | 289 | 1.170 |
Why?
|
| Telemedicine | 5 | 2022 | 526 | 1.080 |
Why?
|
| Health Care Costs | 6 | 2025 | 407 | 0.990 |
Why?
|
| Ambulatory Care | 2 | 2020 | 401 | 0.960 |
Why?
|
| Fractures, Bone | 2 | 2019 | 214 | 0.940 |
Why?
|
| Thyroid Gland | 4 | 2023 | 96 | 0.920 |
Why?
|
| General Surgery | 4 | 2020 | 224 | 0.870 |
Why?
|
| Hyperparathyroidism, Primary | 2 | 2023 | 32 | 0.790 |
Why?
|
| Thyroidectomy | 3 | 2021 | 97 | 0.780 |
Why?
|
| Endocrine System Diseases | 2 | 2022 | 42 | 0.730 |
Why?
|
| Reoperation | 2 | 2025 | 818 | 0.700 |
Why?
|
| Relative Value Scales | 1 | 2021 | 13 | 0.660 |
Why?
|
| Precision Medicine | 2 | 2020 | 388 | 0.610 |
Why?
|
| Hypercalcemia | 1 | 2019 | 41 | 0.600 |
Why?
|
| Cost Savings | 1 | 2019 | 79 | 0.590 |
Why?
|
| Postoperative Care | 1 | 2020 | 294 | 0.560 |
Why?
|
| Critical Care | 2 | 2020 | 686 | 0.550 |
Why?
|
| Pandemics | 4 | 2022 | 1118 | 0.540 |
Why?
|
| Surgical Procedures, Operative | 1 | 2020 | 225 | 0.540 |
Why?
|
| Betacoronavirus | 1 | 2020 | 275 | 0.520 |
Why?
|
| Quality of Health Care | 1 | 2020 | 413 | 0.510 |
Why?
|
| Program Evaluation | 1 | 2018 | 447 | 0.480 |
Why?
|
| Patient Safety | 1 | 2020 | 443 | 0.460 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 339 | 0.460 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 351 | 0.460 |
Why?
|
| Robotic Surgical Procedures | 3 | 2024 | 226 | 0.450 |
Why?
|
| Bone Density | 1 | 2017 | 367 | 0.440 |
Why?
|
| Leadership | 2 | 2020 | 255 | 0.430 |
Why?
|
| Referral and Consultation | 1 | 2018 | 564 | 0.420 |
Why?
|
| Cost-Benefit Analysis | 3 | 2025 | 555 | 0.420 |
Why?
|
| Laparoscopy | 3 | 2024 | 541 | 0.410 |
Why?
|
| Retrospective Studies | 20 | 2025 | 17753 | 0.410 |
Why?
|
| Gastrectomy | 2 | 2025 | 104 | 0.400 |
Why?
|
| Mass Screening | 1 | 2019 | 822 | 0.390 |
Why?
|
| Schools, Medical | 1 | 2014 | 113 | 0.390 |
Why?
|
| Education, Graduate | 1 | 2012 | 20 | 0.370 |
Why?
|
| United States | 12 | 2025 | 12072 | 0.360 |
Why?
|
| Humans | 40 | 2025 | 131163 | 0.350 |
Why?
|
| Lung Neoplasms | 1 | 2021 | 1545 | 0.320 |
Why?
|
| Sexism | 2 | 2020 | 44 | 0.300 |
Why?
|
| Physicians, Women | 2 | 2020 | 54 | 0.290 |
Why?
|
| Internship and Residency | 3 | 2020 | 1223 | 0.280 |
Why?
|
| Analgesics, Opioid | 2 | 2024 | 546 | 0.260 |
Why?
|
| Postoperative Complications | 2 | 2024 | 3147 | 0.240 |
Why?
|
| Obesity | 7 | 2025 | 2426 | 0.230 |
Why?
|
| Female | 23 | 2025 | 70963 | 0.220 |
Why?
|
| Male | 21 | 2025 | 64957 | 0.220 |
Why?
|
| Mastectomy, Segmental | 1 | 2025 | 37 | 0.220 |
Why?
|
| Bupropion | 1 | 2025 | 27 | 0.220 |
Why?
|
| Middle Aged | 15 | 2025 | 28601 | 0.220 |
Why?
|
| Naltrexone | 1 | 2025 | 68 | 0.220 |
Why?
|
| Glucagon-Like Peptides | 1 | 2025 | 40 | 0.220 |
Why?
|
| Surgical Staplers | 1 | 2024 | 2 | 0.210 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2025 | 63 | 0.210 |
Why?
|
| Hernia, Inguinal | 1 | 2024 | 40 | 0.210 |
Why?
|
| Gastroparesis | 1 | 2025 | 70 | 0.210 |
Why?
|
| Herniorrhaphy | 1 | 2024 | 71 | 0.200 |
Why?
|
| Operative Time | 2 | 2023 | 201 | 0.200 |
Why?
|
| Adult | 15 | 2025 | 31282 | 0.200 |
Why?
|
| Prediabetic State | 1 | 2024 | 68 | 0.200 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2024 | 1459 | 0.190 |
Why?
|
| Thyroid Neoplasms | 2 | 2017 | 241 | 0.190 |
Why?
|
| Opioid-Related Disorders | 2 | 2024 | 354 | 0.180 |
Why?
|
| Text Messaging | 1 | 2022 | 42 | 0.170 |
Why?
|
| Phosphorylcholine | 1 | 2021 | 31 | 0.170 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2025 | 245 | 0.170 |
Why?
|
| Antihypertensive Agents | 1 | 2024 | 414 | 0.170 |
Why?
|
| Mobile Applications | 1 | 2022 | 114 | 0.160 |
Why?
|
| Insurance Coverage | 1 | 2021 | 120 | 0.160 |
Why?
|
| Congresses as Topic | 1 | 2021 | 184 | 0.160 |
Why?
|
| Costs and Cost Analysis | 1 | 2020 | 151 | 0.160 |
Why?
|
| Carcinoma, Papillary | 2 | 2017 | 91 | 0.150 |
Why?
|
| Authorship | 1 | 2019 | 30 | 0.150 |
Why?
|
| Peer Review, Research | 1 | 2019 | 45 | 0.150 |
Why?
|
| Asymptomatic Diseases | 1 | 2019 | 77 | 0.150 |
Why?
|
| Models, Economic | 1 | 2019 | 59 | 0.150 |
Why?
|
| Intestinal Obstruction | 1 | 2020 | 86 | 0.150 |
Why?
|
| Parathyroid Hormone | 1 | 2019 | 83 | 0.150 |
Why?
|
| Life Expectancy | 1 | 2019 | 63 | 0.150 |
Why?
|
| Social Media | 1 | 2021 | 120 | 0.150 |
Why?
|
| Cognitive Dysfunction | 1 | 2023 | 338 | 0.140 |
Why?
|
| Aged | 7 | 2025 | 21025 | 0.140 |
Why?
|
| Intestine, Small | 1 | 2020 | 291 | 0.140 |
Why?
|
| Delayed Diagnosis | 1 | 2019 | 131 | 0.140 |
Why?
|
| Body Mass Index | 4 | 2025 | 1717 | 0.140 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2024 | 744 | 0.130 |
Why?
|
| Cohort Studies | 3 | 2024 | 5063 | 0.130 |
Why?
|
| Health Services Accessibility | 1 | 2024 | 712 | 0.130 |
Why?
|
| California | 1 | 2017 | 127 | 0.130 |
Why?
|
| Biopsy | 1 | 2021 | 1239 | 0.130 |
Why?
|
| Intensive Care Units | 1 | 2020 | 526 | 0.120 |
Why?
|
| Treatment Failure | 1 | 2017 | 351 | 0.120 |
Why?
|
| Specialties, Surgical | 2 | 2014 | 90 | 0.110 |
Why?
|
| Hypertension | 1 | 2024 | 1356 | 0.110 |
Why?
|
| Patient Satisfaction | 1 | 2018 | 464 | 0.110 |
Why?
|
| Educational Technology | 1 | 2014 | 6 | 0.110 |
Why?
|
| Faculty, Medical | 2 | 2020 | 281 | 0.110 |
Why?
|
| Teaching Materials | 1 | 2014 | 18 | 0.110 |
Why?
|
| Calcium | 1 | 2019 | 1010 | 0.110 |
Why?
|
| Ultrasonography | 1 | 2017 | 943 | 0.100 |
Why?
|
| Thyroid Nodule | 1 | 2013 | 21 | 0.100 |
Why?
|
| Lung | 1 | 2021 | 1535 | 0.090 |
Why?
|
| Breast Neoplasms | 1 | 2025 | 2602 | 0.090 |
Why?
|
| Economics | 1 | 2012 | 12 | 0.090 |
Why?
|
| Education, Public Health Professional | 1 | 2012 | 6 | 0.090 |
Why?
|
| Science | 1 | 2012 | 36 | 0.090 |
Why?
|
| Biomedical Technology | 2 | 2022 | 38 | 0.080 |
Why?
|
| Time Factors | 1 | 2021 | 6196 | 0.080 |
Why?
|
| Carcinoma | 1 | 2013 | 291 | 0.080 |
Why?
|
| Societies, Medical | 1 | 2014 | 798 | 0.080 |
Why?
|
| Education, Medical, Graduate | 1 | 2014 | 554 | 0.080 |
Why?
|
| Curriculum | 1 | 2014 | 798 | 0.070 |
Why?
|
| Clinical Competence | 1 | 2014 | 1050 | 0.060 |
Why?
|
| Mastectomy | 1 | 2025 | 75 | 0.060 |
Why?
|
| Margins of Excision | 1 | 2025 | 60 | 0.050 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2025 | 77 | 0.050 |
Why?
|
| Surgical Stapling | 1 | 2024 | 18 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2024 | 12936 | 0.050 |
Why?
|
| Parathyroid Glands | 1 | 2023 | 26 | 0.050 |
Why?
|
| Observational Studies as Topic | 1 | 2024 | 106 | 0.050 |
Why?
|
| Qualitative Research | 2 | 2020 | 730 | 0.050 |
Why?
|
| Learning Curve | 1 | 2023 | 54 | 0.050 |
Why?
|
| Remission Induction | 1 | 2023 | 306 | 0.050 |
Why?
|
| Smartphone | 1 | 2022 | 52 | 0.040 |
Why?
|
| Drug Prescriptions | 1 | 2023 | 237 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2025 | 1490 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2022 | 209 | 0.040 |
Why?
|
| Technology | 1 | 2020 | 68 | 0.040 |
Why?
|
| Patient-Centered Care | 1 | 2022 | 236 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2023 | 514 | 0.040 |
Why?
|
| Interviews as Topic | 1 | 2020 | 466 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2025 | 1272 | 0.030 |
Why?
|
| Perception | 1 | 2020 | 231 | 0.030 |
Why?
|
| Healthcare Disparities | 1 | 2024 | 523 | 0.030 |
Why?
|
| Incidence | 1 | 2025 | 3360 | 0.030 |
Why?
|
| Family | 1 | 2020 | 589 | 0.030 |
Why?
|
| Disease Progression | 1 | 2022 | 2200 | 0.030 |
Why?
|
| Young Adult | 2 | 2024 | 10103 | 0.030 |
Why?
|
| Quality Improvement | 1 | 2020 | 722 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 2904 | 0.030 |
Why?
|
| Quality of Life | 1 | 2023 | 2082 | 0.020 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2013 | 101 | 0.020 |
Why?
|
| Data Collection | 1 | 2014 | 370 | 0.020 |
Why?
|
| Ultrasonography, Doppler | 1 | 2013 | 187 | 0.020 |
Why?
|
| Self Report | 1 | 2014 | 554 | 0.020 |
Why?
|
| Adolescent | 2 | 2024 | 20987 | 0.020 |
Why?
|
| Education, Medical | 1 | 2013 | 293 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2014 | 3829 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2013 | 5196 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2013 | 6797 | 0.010 |
Why?
|
| Child | 1 | 2013 | 26341 | 0.010 |
Why?
|